Details for New Drug Application (NDA): 022025
✉ Email this page to a colleague
The generic ingredient in TOTECT is dexrazoxane hydrochloride. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dexrazoxane hydrochloride profile page.
Summary for 022025
Tradename: | TOTECT |
Applicant: | Clinigen |
Ingredient: | dexrazoxane hydrochloride |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 022025
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Sep 6, 2007 | TE: | RLD: | Yes |
Expired US Patents for NDA 022025
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Clinigen | TOTECT | dexrazoxane hydrochloride | INJECTABLE;INJECTION | 022025-001 | Sep 6, 2007 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription